ImageneBio Inc
NASDAQ:IMABiotechnology
+$0.35 today
- Market cap
- $52.00M
- Beta
- 0.72
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.02
Volume 0.00M
Average 0.35M
IMA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ImageneBio IncNASDAQ: IMA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $5.96M rose 60.5% year over year, ahead of the +23.4% change in trailing-twelve-month research & development. Sequentially, it rose 14.0% from the prior quarter. Over 3 fiscal years it compounded at -23.7% a year.
Context
- Research & development amounted to 3565.6% of revenue in FY2025, up 2648.2 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +60.5% holds above the trailing-twelve-month pace of +23.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 28.53M USD
- Year-over-year change
- -11.2%
- 4-year CAGR
- -11.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.53M | -11.2% |
| FY2024 | 2024-12-31 | 32.11M | -46.2% |
| FY2023 | 2023-12-31 | 59.65M | -7.3% |
| FY2022 | 2022-12-31 | 64.32M | +36.5% |
| FY2021 | 2021-12-31 | 47.11M | — |
Research & Development vs competitors
How IMA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.4% is the 4th highest of 9, against a peer median of -19.0%.
- Over three fiscal years its annual growth of -23.7% compares with a peer median of +4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.37M USD | -38.7% | +6.7% | 152.0% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $71.8M USD | +27.7% | +16.5% | — |
| FY2025 | $37.8M USD | +29.2% | -26.9% | 59059.4% | |
| LTM Mar 2026 | $36.3M USD | -40.4% | -24.8% | 3629.9% | |
| LTM Mar 2026 | $35.41M USD | +46.4% | +65.0% | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $32.3M USD | -29.1% | +37.8% | — |
IMAImageneBio Inc | LTM Mar 2026 | $30.77M USD | +23.4% | -23.7% | — |
| LTM Mar 2026 | $30.07M USD | -8.9% | +1.3% | 422.2% | |
| LTM Mar 2026 | €22.87M EUR | -34.8% | -11.8% | 77989.1% | |
| Peer median (excluding IMA) | — | -19.0% | +4.0% | 3629.9% | |
Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.99M | 15.62M | 9.16M | 3.5M | 800K |
| Cost of Revenue | 47.11M | 64.32M | 1.02M | 1.53M | 1.03M |
| Gross Profit | (16.12M) | (48.7M) | 8.14M | 3.5M | (233K) |
| Gross Margin | -52.0% | -311.8% | 88.9% | 100.0% | -29.1% |
| Research & Development | 47.11M | 64.32M | 59.65M | 32.11M | 28.53M |
| Selling, General & Admin | 18.02M | 22.2M | 24.93M | 8.39M | 20.73M |
| Operating Expenses | 18.02M | 22.2M | 83.56M | 40.5M | 48.22M |
| Depreciation & Amortization | 544K | 751K | 1.02M | 1.53M | 1.03M |
| EBITDA | (33.57M) | (68.01M) | (67.31M) | (35.03M) | (44.67M) |
| EBITDA Margin | -108.3% | -435.5% | -734.8% | -1000.8% | -5583.3% |
| Operating Income | (34.14M) | (70.9M) | (75.42M) | (37M) | (48.45M) |
| Operating Margin | -110.2% | -454.0% | -823.3% | -1057.1% | -6056.4% |
| Interest Income | 23K | 2.15M | 7.11M | 7.37M | 2.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 23K | 2.14M | 7.09M | 445K | 2.75M |
| Income Before Tax | (34.12M) | (68.77M) | (68.33M) | (36.56M) | (45.7M) |
| Pre-Tax Margin | -110.1% | -440.3% | -745.9% | -1044.4% | -5712.4% |
| Income Tax Expense | 0 | 0 | (162K) | 13K | (350K) |
| Net Income | (34.12M) | (68.77M) | (68.17M) | (36.57M) | (45.35M) |
| Net Margin | -110.1% | -440.3% | -744.2% | -1044.8% | -5668.6% |
| EPS (Basic) | (0.95) | (1.90) | (1.63) | (1.02) | (10.76) |
| EPS (Diluted) | (0.95) | (1.90) | (1.63) | (1.02) | (10.76) |
| Weighted Avg Shares | 35.98M | 36.19M | 41.74M | 48.26M | 4.87M |
| Weighted Avg Shares (Diluted) | 35.98M | 36.19M | 41.74M | 48.26M | 4.87M |
ImageneBio Inc
NASDAQ:IMA
Intrinsic Alpha fair value
Locked
Current Price
$4.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.